Cargando…

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies

Approximately 15% of all cancer patients harbor mutated KRAS. Direct inhibitors of KRAS have now been generated and are beginning to make progress through clinical trials. These include a suite of inhibitors targeting the KRAS(G12C) mutation commonly found in lung cancer. We investigated emergent re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warren, Hannah R., Ross, Sarah J., Smith, Paul D., Coulson, Judy M., Prior, Ian A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2022
Materias:	Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555794/ https://www.ncbi.nlm.nih.gov/pubmed/36065754 http://dx.doi.org/10.1042/BCJ20220440

Ejemplares similares

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
por: Verissimo, Carla S, et al.
Publicado: (2016)

Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer
por: Chretien, Anne-Sophie, et al.
Publicado: (2013)

Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion
por: Harada, Akikazu, et al.
Publicado: (2021)

Targeting the PI3K signaling pathway in KRAS mutant colon cancer
por: Hong, Suntaek, et al.
Publicado: (2015)

A combinatorial strategy for treating KRAS mutant lung cancer
por: Manchado, Eusebio, et al.
Publicado: (2016)

Pancreatic cyst fluid harboring a KRAS mutation
por: Al-Turkmani, M. Rabie, et al.
Publicado: (2019)

Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival
por: Wang, Danyang, et al.
Publicado: (2021)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies
por: Hwang, Justin H, et al.
Publicado: (2022)

DNA methylation‐regulated and tumor‐suppressive roles of miR‐487b in colorectal cancer via targeting MYC, SUZ12, and KRAS
por: Chen, Xu, et al.
Publicado: (2019)

Targeting centrosome amplification, an Achilles' heel of cancer
por: Sabat-Pośpiech, Dorota, et al.
Publicado: (2019)

Arid1a restrains Kras-dependent changes in acinar cell identity
por: Livshits, Geulah, et al.
Publicado: (2018)

Danger zone
por: Butt, Zohra, et al.
Publicado: (2021)

Quantification of spatiotemporal patterns of Ras isoform expression during development
por: Newlaczyl, Anna U., et al.
Publicado: (2017)

RAS variant signalling
por: Mo, Stephanie P., et al.
Publicado: (2018)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
por: Kato, Junko, et al.
Publicado: (2016)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

ahctf1 and kras mutations combine to amplify oncogenic stress and restrict liver overgrowth in a zebrafish model of hepatocellular carcinoma
por: Morgan, Kimberly J, et al.
Publicado: (2023)

Targeting KRAS mutant cancers: from druggable therapy to drug resistance
por: Zhu, Chunxiao, et al.
Publicado: (2022)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
por: Le Roux, Özgün, et al.
Publicado: (2022)

Targeting the untargetable KRAS in cancer therapy
por: Liu, Pingyu, et al.
Publicado: (2019)

Oncologists' attitudes toward KRAS testing: a multisite study
por: Harris, Julie N, et al.
Publicado: (2013)

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
por: Strickler, John H, et al.
Publicado: (2023)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
por: Xie, Wenli, et al.
Publicado: (2019)

Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior
por: Goswami, Debanjan, et al.
Publicado: (2020)

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer
por: Hsu, Hung‐Chih, et al.
Publicado: (2019)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

Combinatorial Approaches to Viral Attenuation
por: Paff, Matthew L., et al.
Publicado: (2018)

Single-PanIN-seq unveils that ARID1A deficiency promotes pancreatic tumorigenesis by attenuating KRAS-induced senescence
por: Liu, Shou, et al.
Publicado: (2021)

EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS (G12D) tumor development and propagation
por: Pribluda, Ariel, et al.
Publicado: (2022)

Regulation of the cell cycle and centrosome biology by deubiquitylases
por: Darling, Sarah, et al.
Publicado: (2017)

Strategy to targeting the immune resistance and novel therapy in colorectal cancer
por: Gang, Wang, et al.
Publicado: (2018)

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022)

RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy
por: Radaszkiewicz, Tomasz, et al.
Publicado: (2021)

Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
por: Etnyre, Deven, et al.
Publicado: (2014)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer
por: Miller, Abigail L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ikbciq4vq7t8bo5obe1daublg8